Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Massachusetts General Hospital
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07496463CT.gov Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a) | — | Not Yet Recruiting | — | — | — |
NCT06772597CT.gov A Study of Setmelanotide in Patients With Prader-Willi Syndrome | — | Active Not Recruiting | — | — | — |
NCT05093634CT.gov EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | — | Active Not Recruiting | — | — | — |
NCT03262610CT.gov Setmelanotide in a Single Patient With Partial Lipodystrophy | — | Completed | — | — | — |
NCT03013543CT.gov Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity | — | Completed | — | — | — |
NCT02041195CT.gov Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients | — | Completed | — | — | — |
NCT01867437CT.gov Effects of RM-493 on Energy Expenditure in Obese Individuals | — | Completed | — | — | — |
NCT01749137CT.gov Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants | — | Completed | — | — | — |
NCT02431442CT.gov Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers | — | Completed | — | — | — |
NCT05183802CT.gov An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS) | — | Approved For Marketing | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Setmelanotide (this asset) | Massachusetts General Hospital | P3 | B · 63 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Setmelanotide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bardet-Biedl Syndrome | — | P4 | A · 81 |
| Alstrom Syndrome | — | P4 | BBB · 75 |
| Inherited Obesity | — | P3 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Setmelanotide in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/setmelanotide-obesity-disorder-47119
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →